Dry Age-Related Macular Degeneration AMD Companies

Top Industry Leaders in the Dry Age-Related Macular Degeneration AMD Market

*Disclaimer: List of key companies in no particular orderLatest Dry age-related macular degeneration Companies Update

July 2023: To make its worldwide organization as competitive as feasible, Santen Pharmaceutical Co. Ltd. has decided to sell its North American branded ophthalmic inventory to Visiox Pharma LLC and Harrow Health Inc. To manufacture, market, and sell OMLONTI®, an eye drop used to lower increased intraocular pressure (IOP) in people with glaucoma or ocular hypertension, Santen has reached an out-licensing agreement with Visiox Pharmaceuticals, Inc. According to the contract's provisions, Santen gives Visiox the only authority to manufacture and market OMLONTI® products in the United States. Santen is entitled to royalty payments on gross U.S. sales of OMLONTI® as well as sales milestone payments.

Sep 2023: XIIDRA® (lifitegrast ophthalmic solution) five percent, a non-steroid eye drops specifically approved to treat symptoms and signs of dry eye disease with a focus on inflammation associated with dry eye, as well as some other ophthalmology assets, have been acquired by Bausch + Lomb Corporation, a division of Bausch Health Companies. Following the terms of the contract, Bausch + Lomb acquired XIIDRA® and the other eye care assets from Novartis through an affiliate for up to $2.5 billion, including a cash payment of $1.75 billion upfront and potential milestone responsibilities of up to $750 million according to sales limits and pipeline commercialization. The closure of the transaction took place roughly concurrently with the issuing of the Notes and the completion of the Term Loan Facility.

List of Dry age-related macular degeneration Key companies in the market